Your browser doesn't support javascript.
loading
Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies.
LaBranche, Celia C; Henderson, Rory; Hsu, Allen; Behrens, Shay; Chen, Xuejun; Zhou, Tongqing; Wiehe, Kevin; Saunders, Kevin O; Alam, S Munir; Bonsignori, Mattia; Borgnia, Mario J; Sattentau, Quentin J; Eaton, Amanda; Greene, Kelli; Gao, Hongmei; Liao, Hua-Xin; Williams, Wilton B; Peacock, James; Tang, Haili; Perez, Lautaro G; Edwards, Robert J; Kepler, Thomas B; Korber, Bette T; Kwong, Peter D; Mascola, John R; Acharya, Priyamvada; Haynes, Barton F; Montefiori, David C.
Afiliação
  • LaBranche CC; Department of Surgery, Duke University Medical Center, Durham, NC, United States of America.
  • Henderson R; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America.
  • Hsu A; Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC, United States of America.
  • Behrens S; Department of Surgery, Duke University Medical Center, Durham, NC, United States of America.
  • Chen X; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Zhou T; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America.
  • Wiehe K; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America.
  • Saunders KO; Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.
  • Alam SM; Department of Surgery, Duke University Medical Center, Durham, NC, United States of America.
  • Bonsignori M; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America.
  • Borgnia MJ; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America.
  • Sattentau QJ; Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.
  • Eaton A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America.
  • Greene K; Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.
  • Gao H; Genome Integrity and Structural Biology Laboratory, National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services, Research Triangle Park, NC, United States of America.
  • Liao HX; The Sir William Dunn School of Pathology, University of Oxford, Oxford, United Kingdom.
  • Williams WB; Department of Surgery, Duke University Medical Center, Durham, NC, United States of America.
  • Peacock J; Department of Surgery, Duke University Medical Center, Durham, NC, United States of America.
  • Tang H; Department of Surgery, Duke University Medical Center, Durham, NC, United States of America.
  • Perez LG; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America.
  • Edwards RJ; Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.
  • Kepler TB; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America.
  • Korber BT; Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.
  • Kwong PD; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America.
  • Mascola JR; Department of Medicine, Duke University Medical Center, Durham, NC, United States of America.
  • Acharya P; Department of Surgery, Duke University Medical Center, Durham, NC, United States of America.
  • Haynes BF; Department of Surgery, Duke University Medical Center, Durham, NC, United States of America.
  • Montefiori DC; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC, United States of America.
PLoS Pathog ; 15(9): e1008026, 2019 09.
Article em En | MEDLINE | ID: mdl-31527908
ABSTRACT
The CD4 binding site (CD4bs) of the HIV-1 envelope glycoprotein is susceptible to multiple lineages of broadly neutralizing antibodies (bnAbs) that are attractive to elicit with vaccines. The CH235 lineage (VH1-46) of CD4bs bnAbs is particularly attractive because the most mature members neutralize 90% of circulating strains, do not possess long HCDR3 regions, and do not contain insertions and deletions that may be difficult to induce. We used virus neutralization to measure the interaction of CH235 unmutated common ancestor (CH235 UCA) with functional Env trimers on infectious virions to guide immunogen design for this bnAb lineage. Two Env mutations were identified, one in loop D (N279K) and another in V5 (G458Y), that acted synergistically to render autologous CH505 transmitted/founder virus susceptible to neutralization by CH235 UCA. Man5-enriched N-glycans provided additional synergy for neutralization. CH235 UCA bound with nanomolar affinity to corresponding soluble native-like Env trimers as candidate immunogens. A cryo-EM structure of CH235 UCA bound to Man5-enriched CH505.N279K.G458Y.SOSIP.664 revealed interactions of the antibody light chain complementarity determining region 3 (CDR L3) with the engineered Env loops D and V5. These results demonstrate that virus neutralization can directly inform vaccine design and suggest a germline targeting and reverse engineering strategy to initiate and mature the CH235 bnAb lineage.
Assuntos

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Produtos do Gene env do Vírus da Imunodeficiência Humana / Anticorpos Amplamente Neutralizantes Limite: Humans Idioma: En Revista: PLoS Pathog Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Anticorpos Anti-HIV / HIV-1 / Vacinas contra a AIDS / Produtos do Gene env do Vírus da Imunodeficiência Humana / Anticorpos Amplamente Neutralizantes Limite: Humans Idioma: En Revista: PLoS Pathog Ano de publicação: 2019 Tipo de documento: Article